Defining the economic burden and the pathophysiology of type 2 inflammation in asthma.
A discussion on the diagnostic process and the biomarkers commonly tested in asthma.
There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations.
January 16th 2021, 12:30pm
A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.
January 15th 2021, 5:03pm
Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.
January 10th 2021, 7:30pm
Patients often ask how long they have to stay on biologic treatment for atopic dermatitis (AD), but there is a risk if therapy is stopped, says Matthew J. Zirwas, MD, a dermatologist in Ohio.
January 8th 2021, 5:10pm
A review explored the potential role of eosinophils and their mediators in the pathophysiology of chronic rhinosinusitis (CRS) subtypes.
December 31st 2020, 9:45pm
Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.
December 27th 2020, 4:15pm
The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).
December 26th 2020, 10:30pm
In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.
December 23rd 2020, 1:00pm
This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.
December 19th 2020, 2:30pm
The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.
December 18th 2020, 3:45pm
The treatment landscape for atopic dermatitis is beginning to change from the use of topical therapies to biologics and more, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
